SCHEMBL15613538

SCHEMBL15613538

Cc1ncc(COc2cc(F)cc(Oc3ccc(-c4nn(CCO)c5ncnc(N)c45)cc3)c2)n1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 8/20 0.48
▸ HCK P08631 4/20 0.48
▸ EGFR P00533 3/20 0.48
▸ PIK3CD O00329 3/20 0.48
▸ PIK3CA P42336 2/20 0.48
▸ PIK3CB P42338 2/20 0.48
▸ PIK3CG P48736 2/20 0.48
▸ PRKDC P78527 2/20 0.48
▸ ABL1 P00519 1/20 0.48
▸ KDR P35968 1/20 0.48
▸ MTOR P42345 1/20 0.48
▸ EPHB4 P54760 1/20 0.48
▸ PI4KB Q9UBF8 1/20 0.48
▸ BTK Q06187 11/20 0.46
▸ LCK P06239 4/20 0.45
▸ ITK Q08881 3/20 0.45
▸ JAK3 P52333 2/20 0.45
▸ NUDT14 O95848 1/20 0.44
▸ NUDT5 Q9UKK9 1/20 0.44
▸ FGR P09769 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15613656 0.90 CYP1A2 (0.46) SRCEGFRPIK3CDPIK3CAPIK3CB
SCHEMBL15613525 0.87 SRC (0.48) SRCHCKEGFRPIK3CDPIK3CA
SCHEMBL15613536 0.87 BTK (0.50) SRCHCKEGFRPIK3CDPIK3CA
SCHEMBL15613560 0.86 SRC (0.54) SRCHCKEGFRPIK3CDPIK3CA
SCHEMBL15613563 0.86 KCNH2 (0.53) SRCHCKEGFRPIK3CDPIK3CA
SCHEMBL15613545 0.86 SRC (0.48) SRCHCKEGFRPIK3CDPIK3CA
SCHEMBL15613521 0.85 SRC (0.47) SRCHCKEGFRPIK3CDPIK3CA
SCHEMBL16886182 0.85 SRC (0.49) SRCHCKEGFRPIK3CDPIK3CA
SCHEMBL15613655 0.84 BTK (0.59) SRCHCKEGFRPIK3CDPIK3CA
SCHEMBL15613642 0.83 BTK (0.45) SRCHCKEGFRPIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
WO-2013177668-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2013-12-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191473-A1 PROTEIN KINASE INHIBITORS TEC, SRC, LCK SRC 2/4885HCK 47/4885EGFR 521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback